BMS is a New York-based biopharmaceutical firm that develops and commercializes medicines for treating patients prevail over serious diseases.Read more
BMS's revenue is the ranked 9th among it's top 10 competitors. The top 10 competitors average 42.6B. Over the last four quarters, BMS's revenue has decreased by $-55000000. Specifically, in Q1 2022's revenue was $11.6B; in Q4 2021, it was $12B; in Q3 2021, it was $11.6B; in Q2 2021, BMS's revenue was $11.7B.